NMN/NR (Nicotinamide Mononucleotide/Riboside) and Cannabis: Complete Interaction Profile

What Is the Interaction Class Between NMN/NR and Cannabis?

The NMN/NR-cannabis combination falls into two interaction categories: pharmacokinetic (shared hepatic enzyme pathways) and pharmacodynamic (opposing or additive effects on the same biological targets). No head-to-head clinical trial has enrolled patients on both agents simultaneously, so every statement below is derived from individual pharmacology data rather than co-administration studies.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both orally administered precursors to NAD+, the redox coenzyme central to mitochondrial respiration and sirtuin-mediated gene regulation [1]. Cannabis delivers primarily THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol), each with distinct metabolic fingerprints [2].

Why Pharmacokinetic Overlap Matters

THC is metabolized first to 11-OH-THC and then to 11-nor-9-carboxy-THC principally by CYP2C9 and CYP3A4 [2]. CBD is a well-characterized inhibitor of CYP2C9, CYP2C19, and CYP3A4 at plasma concentrations achievable with typical inhaled or oral doses [3]. NMN undergoes intracellular phosphorylation to NAD+ via NMNAT enzymes rather than classical hepatic CYP oxidation, so the direct CYP competition between NMN itself and THC/CBD is low [1].

NR follows a slightly different path: it is first converted to NMN by NRK1/NRK2 kinases, or alternatively cleaved to nicotinamide, which re-enters the salvage pathway [4]. Neither route involves CYP2C9 or CYP3A4 in a clinically meaningful way. The pharmacokinetic risk is therefore modest and primarily runs in one direction: CBD may slow THC clearance, not the other way around.

What Changes at the Pharmacodynamic Level

Both NMN/NR and cannabinoids touch the SIRT1 deacetylase pathway. NMN raises intracellular NAD+, which activates SIRT1 [1]. CBD has been shown in rodent hepatocyte studies to modulate SIRT1 expression through a separate CB1-independent mechanism [5]. The net effect of simultaneous activation through two separate mechanisms is not established, and either additive or opposing outcomes are plausible depending on tissue and dose.

How Does Cannabis Affect NAD+ Metabolism Specifically?

Cannabis and NAD+ interact at several nodes. Chronic THC exposure in preclinical models suppresses mitochondrial complex I activity, which increases NADH and decreases the NAD+/NADH ratio [6]. A lower NAD+/NADH ratio is precisely the deficiency that NMN/NR supplementation aims to correct [1]. This means chronic, heavy cannabis use could theoretically reduce the benefit of NMN/NR by continuously re-depleting the NAD+ pool.

The PARP Connection

Oxidative stress driven by THC metabolites activates poly(ADP-ribose) polymerase (PARP), an enzyme that consumes NAD+ to repair DNA strand breaks [7]. PARP hyperactivation is one of the recognized mechanisms of NAD+ depletion in aging tissue [4]. A person using cannabis daily and supplementing with NMN/NR may find the supplementation's benefit partially canceled because the NAD+ generated is being consumed by PARP activation triggered by the same cannabis use. This is a mechanistic hypothesis, not a confirmed clinical finding, but it is consistent with published data on each pathway individually.

CD38 and Inflammation

THC and CBD both modulate neuroinflammation through CB1 and CB2 receptors [2]. CD38, the ectoenzyme responsible for a large fraction of age-related NAD+ decline, is upregulated by pro-inflammatory signaling [8]. If cannabis-driven receptor activity shifts cytokine profiles, CD38 expression could change, further altering how much NAD+ is available after NMN/NR dosing. A 2020 paper in Nature Metabolism identified CD38 as a dominant NAD+-consuming enzyme in aging tissues, with expression driven by SASP-related inflammation [8].

Cardiovascular Overlap: The Most Clinically Relevant Concern

Acute THC use raises heart rate by 20 to 50 beats per minute within minutes of inhalation and may cause transient hypertension followed by orthostatic hypotension [9]. This effect is mediated primarily through CB1 receptor activation in cardiac tissue and sympathetic nervous system stimulation [9].

NMN at doses studied in humans (250 mg to 1,200 mg per day) has not produced consistent cardiovascular changes in published trials, but rodent data show that NAD+ repletion improves endothelial nitric oxide synthesis, which has a vasodilatory effect [10]. The combination of THC-induced tachycardia and endothelial vasodilation from NMN/NR could in theory produce unpredictable blood pressure responses, particularly in older adults or those with pre-existing cardiac conditions.

Relevant Human Trial Data for NMN

In a 2020 randomized, double-blind, placebo-controlled crossover trial (N=10 healthy men, age 65 or older), NMN 250 mg once daily for 10 weeks significantly increased skeletal muscle NAD+ metabolite concentrations and improved insulin sensitivity without significant changes in resting heart rate or blood pressure [11]. However, the trial excluded cannabis users, so no safety data exists for the combined exposure.

Relevant Human Trial Data for Cannabis Cardiovascular Effects

A 2021 systematic review in the Journal of the American Heart Association examined cardiovascular outcomes across 36 observational studies and found acute cannabis use associated with a 1.5- to 3.7-fold increase in myocardial infarction risk in the hours immediately following use, primarily driven by tachycardia and increased myocardial oxygen demand [9]. The authors noted that the absolute risk remains low in young, healthy users but rises substantially in adults over 50 with cardiovascular risk factors [9].

Who Faces the Highest Risk

Patients who fall into any of the following categories should discuss both agents explicitly with their clinician before combining them: adults over 55, anyone with a resting heart rate above 90 bpm, anyone with diagnosed coronary artery disease, and anyone on concomitant adrenergic agents or beta-blockers.

Hepatic and Enzyme Considerations

NR metabolism generates free nicotinamide as a byproduct, and at high doses, nicotinamide can inhibit SIRT1 in a negative-feedback loop [4]. CBD at doses above approximately 300 mg per day has been shown in clinical pharmacokinetic studies to raise liver transaminases, particularly when co-administered with other hepatically processed compounds [3]. The 2018 JAMA paper on Epidiolex (CBD 20 mg/kg/day in pediatric epilepsy patients) reported ALT elevations above three times the upper limit of normal in 13% of patients on concomitant valproate [12].

Although NMN/NR is not valproate, the point stands: CBD at therapeutic doses adds hepatic burden. Patients combining high-dose CBD products with NMN/NR should have a baseline liver panel and recheck at 8 to 12 weeks.

Nicotinamide Flushing and THC

Nicotinamide, the downstream metabolite of both NMN and NR, inhibits the GPR109A receptor that mediates niacin-flush. This is distinct from niacin (nicotinic acid) supplementation. THC itself can produce cutaneous vasodilation. The concurrent presence of both agents has not been studied for additive flush or vasodilatory skin responses, but patients who notice pronounced flushing after initiating NMN/NR concurrent with cannabis use should mention it to their clinician.

Sirtuin Pathway: Shared Target, Different Mechanisms

SIRT1 is a NAD+-dependent deacetylase that regulates inflammation, circadian rhythm, glucose metabolism, and mitochondrial biogenesis [1]. NMN/NR raises intracellular NAD+ and thereby increases SIRT1 catalytic activity [1].

THC, through CB1 receptor signaling, activates the ERK1/2 pathway, which phosphorylates and partially inhibits SIRT1 in hippocampal neurons in rodent models [13]. If this mechanism translates to humans, THC could blunt the SIRT1-activating benefit of NMN/NR in neural tissue specifically.

CBD's effect on sirtuins runs in the opposite direction. A 2021 preclinical paper showed CBD increased SIRT1 expression in hepatic stellate cells, reducing fibrogenic markers [5]. CBD and NMN/NR may therefore act additively on SIRT1 in the liver while THC and NMN/NR act in partial opposition in the brain. This tissue-specificity makes a blanket statement about the interaction difficult.

A Practical Tiering Framework for NMN/NR and Cannabis Co-Use

Clinicians reviewing patients on NMN/NR who report cannabis use can apply this three-tier risk stratification:

Tier 1 (Low concern): Occasional cannabis use (fewer than 3 times per week), CBD-dominant products, no cardiovascular history, age <50, no concurrent hepatotoxic agents. No dose adjustment needed; standard NMN/NR monitoring applies.

Tier 2 (Moderate concern): Daily cannabis use or high-THC products, age 50 to 65, or borderline cardiovascular risk factors. Separate NMN/NR dosing from cannabis by at least 2 to 4 hours. Obtain a baseline ECG and liver panel. Reassess at 12 weeks.

Tier 3 (High concern): Daily high-THC use, age over 65, established cardiovascular disease, concurrent CYP3A4-sensitive medications, or elevated baseline transaminases. Consider deferring NMN/NR initiation until cannabis use is quantified and stabilized. Cardiology or hepatology input is appropriate before proceeding.

FDA Regulatory Status and Labeling Implications

The FDA issued a response letter in November 2022 stating that NMN cannot be marketed as a dietary supplement because it was first studied as a drug before being introduced as a supplement (under IND 157,631) [14]. NR (nicotinamide riboside) does not carry the same exclusion and retains dietary supplement status. Neither compound has an FDA-approved labeling section addressing cannabis drug interactions, because cannabis remains a Schedule I substance at the federal level and is absent from standard FDA drug interaction labeling frameworks.

The FDA's cannabis-related guidance, including its 2020 document on CBD, explicitly notes that insufficient data exists to establish safe CBD use in combination with other dietary supplements [15]. This gap directly applies to the NMN/NR plus cannabis question.

Dosing Timing Recommendations

Since the primary pharmacodynamic overlap is cardiovascular (THC-driven tachycardia peaking 10 to 30 minutes after inhalation) and the primary pharmacokinetic concern is CBD-mediated CYP inhibition (which affects other drugs more than NMN/NR itself), timing strategy should focus on the cardiovascular window.

NMN is typically dosed once daily in the morning in most human trials, including the 2023 trial by Yi et al. (N=80, 300 mg NMN vs. Placebo for 60 days) [16]. Separating cannabis use from NMN dosing by 2 to 4 hours keeps the THC cardiovascular peak away from any peak vasodilatory effect of NMN. This is a precautionary spacing recommendation, not a pharmacokinetically required separation, given the metabolic pathways involved.

What About Alcohol on Top of NMN/NR?

Alcohol is metabolized to acetaldehyde by alcohol dehydrogenase and then to acetate by aldehyde dehydrogenase (ALDH2). ALDH2 requires NAD+ as a cofactor [17]. NMN/NR supplementation increases NAD+ availability, which could theoretically accelerate acetaldehyde clearance by ALDH2 and reduce acetaldehyde-mediated toxicity. A 2019 paper in iScience showed that NMN co-administration reduced alcohol-induced liver injury in mice by restoring hepatic NAD+/NADH balance and improving ALDH2 activity [17].

Cannabis combined with alcohol increases peak THC blood concentration by approximately 2.5-fold compared to cannabis alone, a phenomenon documented in a 2015 CPDD study involving 19 participants [18]. A patient combining NMN/NR, alcohol, and cannabis therefore faces a three-way interaction where cannabis-alcohol combination elevates THC exposure while NMN/NR may alter hepatic redox state. No human data covers this triple combination.

Monitoring Parameters for Concurrent Use

Patients choosing to continue both NMN/NR and cannabis should be monitored with the following parameters, adapted from general nutraceutical-drug monitoring principles [4]:

• Resting heart rate at baseline and at 4 to 8 weeks
• Blood pressure (seated and standing) to capture orthostatic changes
• Liver function panel (ALT, AST, ALP, total bilirubin) at baseline and 12 weeks, especially with high-dose CBD products
• Self-reported sleep quality (both NMN/NR and cannabis affect circadian rhythms through SIRT1 and endocannabinoid modulation, respectively)
• Subjective energy and cognitive function, since both agents affect mitochondrial output